Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Granieri, Letizia ^a,b   Marnetto, Fabiana ^a,b   Valentino, Paola ^a,b   Frau, Jessica ^c   Patanella, Agata Katia ^d   Nytrova, Petra ^e   Sola, Patrizia ^f   Capobianco, Marco ^a   Jarius, Sven ^g   Bertolotto, Antonio ^a,b  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e CHARLES UNIVERSITY   (Czech Republic)

^f S Agostino Estense Hospital   (Italy)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ADOLESCENT; ADULT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; BRAIN; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; INTER LABORATORY REPRODUCIBILITY; INTRA LABORATORY REPRODUCIBILITY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NONHUMAN; OPTIC NERVE; PRIMATE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEROLOGY; STANDARDIZATION;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; FLUORESCENT DYES; HUMANS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA;

EID: 84862245318     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038896     Document Type: Article

References (45)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG, (1999) The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53(5): 1107-1114.
2. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG, (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 23: 66(10),1485-1489.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al. (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112.
4. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR, (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477.
5. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, et al. (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59: 566-569.
6. Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, et al. (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298(1-2): 158-162.
7. Petzold A, Pittock S, Lennon V, Maggiore C, Weinshenker BG, et al. (2010) Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 81: 109-111.
8. Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, et al. (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65(1): 78-83.
9. Wandinger KP, Stangel M, Witte T, Venables P, Charles P, et al. (2010) Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum 62(4): 1198-1200.
10. Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, et al. (2011) Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Sclerosis 17(9): 1067-73.
11. Jarius S, Wildemann B, (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6 (7): 383-392.
12. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58 (6): 840-846.
13. Hilliam RM, (2005) Statistical discrimination in the presence of selection effects. Stat Med 24 (8): 1219-1232.
14. Landis JR, Koch GG, (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159-174.
15. Kundel HL, Polansky M, (2003) Measurement of observer agreement. Radiology 228: 303-308.
16. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, et al. (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70: 2197-2200.
17. Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, et al. (2010) IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75(16): 1423-7.
18. Palace J, Leite MI, Nairne A, Vincent A, (2010) Interferon Beta Treatment in Neuromyelitis Optica. Arch Neurol 67(8): 1016-1017.
19. Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, et al. (2012) Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. Arch Neurol 69(2): 239-245.
20. Barnett MH, Prineas JW, Buckland ME, Parratt JDE, Pollard JD, (2012) Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Multiple Sclerosis Journal 18(1) 108-112.
21. Min JH, Kim BJ, Lee KH, (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 18(1) 113-115.
22. Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, et al. (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77(7): 659-66.
23. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, et al. (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17(10): 1225-30.
24. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ, (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68(11): 1412-20.
25. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, et al. (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270-2.
26. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008 65: 1443-8.
27. Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, et al. (2007) NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68 (13): 1076-1077.
28. De Vidi I, Boursier G, Delouche N, Portales P, Cadars E, et al. (2011) Strategy for anti-aquaporin-4 auto-antibody identification and quantification using a new cell-based assay. Clin Immunol 138: 239-246.
29. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, et al. (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130: 1235-1243.
30. Waters P, Jarius S, Littleton E, Leite MI, Jacob S, et al. (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65 (7): 913-919.
31. Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, et al. (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4(4): e133.
32. McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, et al. (2009) Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 66(9): 1134-1138.
33. Hayakawa S, Mori M, Okuta A, Kamegawa A, Fujiyoshi Y, et al. (2008) Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 30: 196(1-2), 181-187.
34. Fazio R, Malosio ML, Lampasona V, De Feo D, Privitera D, et al. (2009) Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients. Mult Scler 15 (10): 1153-1163.
35. Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, et al. (2010) Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 67(10): 1201-1208.
36. Marnetto F, Hellias B, Granieri L, Frau J, Patanella AK, et al. (2009) Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica. J Neuroimmunol 217 (1-2): 74-79.
37. Fazio R, Radaelli M, Furlan R, (2010) Neuromyelitis Optica: Concepts in evolution.J Neuroimmunol 231(1-2): 100-104.
38. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, et al. (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131(Pt 11): 3072-3078.
39. Marignier R, De Seze J, Vukusic S, Durand-Dubief F, Zephir H, et al. (2008) NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler 14 (4): 440-445.
40. Jarius S, Wandinger KP, Borowski K, Stoecker W, Wildemann B, (2012) Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: Case report and review of the literature. Clin Neurol Neurosurg 114(4): 331-5.
41. Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, et al. (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sc 291: 52-56.
42. Kim W, Lee JE, Li XF, Kim SH, Han BG, et al. (2011) Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. Mult Scler Sep 30, in press.
43. Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, et al. (2012) Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9): 665-71.
44. Banwell B, Tenembaum S, Lennon VA, Ursell E, Kennedy J, et al. (2008) Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 70(5):344-52. Epub 2007 Dec 19.
45. Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, et al. (2008) Spectrum of pediatric neuromyelitis optica. Pediatrics 122(5): e1039-47.